C r i b b s e t a l 2
SIGNIFICANCE STATEMENTThe precise regulation of Th17 cell metabolic function is central to an inflammatory response.Following activation, T cells undergo metabolic reprogramming and utilise up-regulated glycolysis to increase the availability of ATP. This work establishes an epigenetic link between the H3K27 demethylases KDM6A/B and the coordination of a metabolic response in activated Th17 cells.Inhibition of KDM6A/B leads to global increases in the repressive H3K27me3 histone mark resulting in down-regulation of key transcription factors, followed by metabolic reprogramming and the induction of anergy in Th17 cells. This work suggests a critical role of KDM6 enzymes in maintaining Th17 functions by controlling metabolic switches, necessary for T cells to adapt to their specific roles. C r i b b s e t a l 3 ABSTRACT T helper (T h ) cells are CD4+ effector T cells that play an instrumental role in immunity by shaping the inflammatory cytokine environment in a variety of physiological and pathological situations. Using a combined chemico-genetic approach we identify histone H3K27 demethylases KDM6A and KDM6B as central regulators of human Th subsets. The prototypic KDM6 inhibitor GSK-J4 increases genome-wide levels of the repressive H3K27me3 chromatin mark and leads to suppression of the key transcription factor RORγt during Th17 differentiation, whereas in mature Th17 cells an altered transcriptional program leads to a profound metabolic reprogramming with concomitant suppression of IL-17 cytokine levels and reduced proliferation. Single cell analysis reveals a specific shift from highly inflammatory cell subsets towards a resting state upon demethylase inhibition. The apparent root cause of the observed anti-inflammatory phenotype in stimulated Th17 cells is reduced expression of key metabolic transcription factors, such as PPRC1 and c-myc. Overall, this leads to reduced mitochondrial biogenesis resulting in a metabolic switch with concomitant anti-inflammatory effects. These data are consistent with an opposing effect of GSK-J4 on Th17 T-cell differentiation pathways directly related to proliferation and effector cytokine profiles.